We are live on ! Find out more
NBIX icon

Neurocrine Biosciences
NBIX

218 hedge funds and large institutions have $3.68B invested in Neurocrine Biosciences in 2017 Q1 according to their latest regulatory filings, with 38 funds opening new positions, 72 increasing their positions, 80 reducing their positions, and 37 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% more capital invested

Capital invested by funds: $3.27B → $3.68B (+$417M)

3% more first-time investments, than exits

New positions opened: 38 | Existing positions closed: 37

0.51% more ownership

Funds ownership: 97.13% → 97.64% (+0.51%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

3% less funds holding

Funds holding: 225 → 218 (-7)

10% less repeat investments, than reductions

Existing positions increased: 72 | Existing positions reduced: 80

39% less call options, than puts

Call options by funds: $12.3M | Put options by funds: $20.3M

Holders
218
Holders Change
-7
Holders Change %
-3.11%
% of All Funds
5.43%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.15%
New
38
Increased
72
Reduced
80
Closed
37
Calls
$12.3M
Puts
$20.3M
Net Calls
-$8.01M
Net Calls Change
-$6.53M

Top Buyers

1
BlackRock
BlackRock
New York
+$214M
2
Wellington Management Group
Wellington Management Group
Massachusetts
+$87.4M
3
JHIU
Janus Henderson Investors US
Colorado
+$85.8M
4
Goldman Sachs
Goldman Sachs
New York
+$42.7M
5
Citadel Advisors
Citadel Advisors
Florida
+$30.7M

Top Sellers

1
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$80M
2
O
OrbiMed
New York
-$72.3M
3
Millennium Management
Millennium Management
New York
-$51.7M
4
Fidelity Investments
Fidelity Investments
Massachusetts
-$39.4M
5
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$26.2M
Name Holding Trade Value Shares
Change 		Change in
Stake
GH
76
GAM Holding
Switzerland
$4.97M +$360K +8,400 +8%
RhumbLine Advisers
77
RhumbLine Advisers
Massachusetts
$4.76M +$113K +2,634 +2%
HRCM
78
Hood River Capital Management
Florida
$4.73M -$4.11M -96,015 -47%
Point72 Asset Management
79
Point72 Asset Management
Connecticut
$4.33M +$4.28M +100,000 New
Axa
80
Axa
France
$4.08M +$4.04M +94,338 New
SC
81
Samlyn Capital
New York
$4.03M +$3.98M +92,983 New
State Board of Administration of Florida Retirement System
82
State Board of Administration of Florida Retirement System
Florida
$3.97M -$23.7K -554 -0.6%
GC
83
Guggenheim Capital
Illinois
$3.84M +$284K +6,620 +8%
TD Asset Management
84
TD Asset Management
Ontario, Canada
$3.79M -$1.94M -45,395 -34%
Loomis, Sayles & Company
85
Loomis, Sayles & Company
Massachusetts
$3.69M +$617K +14,396 +20%
RPAM
86
Rhenman & Partners Asset Management
Sweden
$3.68M +$1.93M +45,000 +113%
GKIM
87
GW&K Investment Management
Massachusetts
$3.67M -$66.6K -1,555 -2%
TA
88
Teachers Advisors
New York
$3.58M +$187K +4,360 +6%
SEI Investments
89
SEI Investments
Pennsylvania
$3.42M +$401K +9,363 +13%
AQR Capital Management
90
AQR Capital Management
Connecticut
$3.4M -$2.96M -69,075 -47%
Principal Financial Group
91
Principal Financial Group
Iowa
$3.29M -$8.31K -194 -0.3%
AA
92
ALPS Advisors
Colorado
$3.25M -$366K -8,538 -10%
SCA
93
Secor Capital Advisors
New York
$3.13M +$29.2K +681 +1%
MOACM
94
Mutual of America Capital Management
New York
$3.08M -$61.8K -1,442 -2%
BG
95
Bellevue Group
Switzerland
$2.94M -$300K -7,000 -9%
CIP
96
Chartwell Investment Partners
Pennsylvania
$2.85M -$3.43M -80,108 -55%
HCMT
97
Highland Capital Management (Texas)
Texas
$2.73M +$2.7M +63,000 New
ICM
98
IronBridge Capital Management
Illinois
$2.62M +$2.59M +60,400 New
DCM
99
DAFNA Capital Management
California
$2.53M -$321K -7,500 -11%
Citigroup
100
Citigroup
New York
$2.34M -$4.87M -113,758 -68%
2 3
4
5 6

NBIX Hedge Fund Activity: Q1 2017 in Review

218 of the 4,017 institutional investors tracked by Wall St. Rank reported a position in Neurocrine Biosciences (NBIX) for Q1 2017, worth a combined $3.68B — up 13% from $3.27B a quarter earlier.

Buyers outnumbered sellers: 38 funds opened new NBIX positions and 37 closed out — a net gain of 1 holder — while 72 added to existing stakes and 80 trimmed.

The largest buyer was BlackRock, adding an estimated $214M. The largest seller was T. Rowe Price Associates, cutting an estimated $80M.

  • 218 institutional investors held Neurocrine Biosciences (NBIX) as of Q1 2017, down from 225 in Q4 2016.
  • Funds reported $3.68B of Neurocrine Biosciences stock for Q1 2017, up 13% quarter-over-quarter.
  • 38 funds opened new Neurocrine Biosciences positions in Q1 2017 and 37 closed out, a net change of +1 holder.
  • The largest Neurocrine Biosciences buyer in Q1 2017 was BlackRock, an estimated $214M added.
  • The largest Neurocrine Biosciences seller in Q1 2017 was T. Rowe Price Associates, an estimated $80M sold.

Based on aggregated 13F filings for Q1 2017.